Medicenna Doses First Patient in MDNA11 Phase 1/2 ABILITY Study
14 sept. 2021 08h00 HE
|
Medicenna Therapeutics Corp.
-- Trial designed to assess safety, pharmacokinetics (PK), pharmacodynamics (PD), and anti-tumor activity of MDNA11 in patients with advanced solid tumors -- Preliminary update on safety, PK/PD, and...
Medicenna Therapeutics to Present at Upcoming September Investor Conferences
09 sept. 2021 09h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today...
Medicenna Reports First Quarter Fiscal 2022 Financial Results and Operational Highlights
13 août 2021 07h00 HE
|
Medicenna Therapeutics Corp.
-- Phase 1/2 ABILITY Study of MDNA11 in patients with advanced solid tumors remains on track for initiation in the third quarter of calendar 2021 -- Management hosting conference call and webcast...
Medicenna to Announce First Quarter Fiscal 2022 Financial Results and Operational Highlights on Friday, August 13, 2021
04 août 2021 09h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Medicenna Announces That Initiation of MDNA11 Phase 1/2 Study is on Track; Update to be Provided at the PropThink Digital Conference
27 juil. 2021 09h00 HE
|
Medicenna Therapeutics Corp.
- Phase 1/2 ABILITY Study is designed to evaluate MDNA11, a potentially best-in-class IL-2 Superkine, in patients with advanced solid tumors - Study to start enrollment in the third quarter of 2021...
Medicenna’s IL-2 Superkine Platform Featured in Peer-Reviewed Publication Demonstrating its Superiority and Ability to Reprogram the Tumor Microenvironment in Pancreatic Cancer
14 juil. 2021 09h00 HE
|
Medicenna Therapeutics Corp.
-- Preclinical results in a pancreatic cancer model show that MDNA109, delivered by an oncolytic adenovirus, induced superior anti-tumor response with tendency towards complete tumor regression,...
Medicenna Announces Submission of Clinical Trial Application in Australia for a Phase 1/2 Study of MDNA11
23 juin 2021 09h00 HE
|
Medicenna Therapeutics Corp.
-- Initiation of the ABILITY Study, a first-in-human trial, is expected in the third quarter of 2021 -- Trial is designed to assess the safety, pharmacokinetics (PK), pharmacodynamics (PD), and...
Medicenna Reports Fiscal Year 2021 Financial Results and Operational Highlights
28 mai 2021 07h30 HE
|
Medicenna Therapeutics Corp.
-- Management hosting conference call and webcast today at 8:30 AM ET TORONTO and HOUSTON, May 28, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”)...
Medicenna to Announce Fiscal Year 2021 Financial Results and Operational Highlights on Friday, May 28, 2021
20 mai 2021 09h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, May 20, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...
Medicenna Appoints Immuno-Oncology Expert Dr. Mann Muhsin as Chief Medical Officer
12 mai 2021 09h00 HE
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced...